



Overview

- Definition
 - A chronic, relapsing inflammatory disorder of unknown etiology with classic triad findings
 - Recurrent oral and genital aphthous ulcers
 - Ocular inflammation
 - Skin lesions
 - International criteria:
 - Behçet's Research Committee of Japan
 - Complete, incomplete, suspect, possible
 - International Study Group for Behçet's Disease Criteria
 - Oral ulcers +2 of: genital ulcers, eye lesions, skins lesions, pathergy test
 - Frequently involves CNS and GI tract as well
 - Ocular inflammation in 67–95%
 - Anterior uveitis
 - Devastating retinal vasculitis
- Symptoms
 - Blurring
 - Scotomas
 - Redness
 - Periorbital pain
 - Photophobia
 - Tearing with rare ocular discharge
 - Diplopia (with neurologic involvement)
- Laterality
 - Unilateral progressing to bilateral, 80%

- Course
 - Recurrent inflammation, not typically chronic
 - Ocular flares are often severe
- Age of onset
 - 25–35 years worldwide (range 2 months to 72 years)
- Gender/race
 - Historically M > F, may be more even distribution
 - Most common in Eastern Mediterranean and East Asian
- Systemic association
 - Systemic vasculitis
 - Oral and/or genital aphthous ulcers
 - Various mild to severe organ involvement including skin, heart, CNS, GI, lungs, GU, joints

Exam: Ocular

Anterior Segment

- Acute anterior uveitis (AU):
 - Non-granulomatous
 - May progress to “shifting” hypopyon if untreated, 19–31%
- More common:
 - Cataract
 - Posterior synechiae
 - Peripheral anterior synechiae
 - Iris atrophy
- Less common:
 - Scleritis
 - Episcleritis
 - Filamentary keratitis
 - Neovascularization of iris
 - From posterior inflammation
 - Poor prognostic sign

Posterior Segment

- Posterior or panuveitis
 - Vitritis with acute inflammation
- Retinal and/or vitreous hemorrhage
- Venous and capillary dilatation
- Obliterative necrotizing retinal vasculitis (RV)
 - May involve arteries and veins simultaneously (also capillaries)
 - Ghost vessels, “silver-wired” vessels

- CRVO or BRVO
- CRAO or BRAO
- NVE, NVD
- CME
- Chorioretinal scarring
- Retinal tears and detachment
- Papillitis, later progressive optic atrophy
- Neovascular glaucoma

Exam: Systemic

- Oral aphthous ulcers, required for diagnosis
- Skin
 - Erythema nodosum
 - Hyperpigmented/hypopigmented scarring
 - Pathergy (40%)
 - Acne vulgaris or folliculitis, on thorax or face
- Vasculitis (8–38%)
 - Any vessels (arteries, veins, capillaries), any size
 - Superficial thrombophlebitis, upper or lower extremities
- Neurologic (3–10%, neurologic or vascular in origin)
 - Cranial nerve palsies (CN VI, CN VII, transient)
 - Papillitis, papilledema
 - Audiovestibular dysfunction
 - Venous sinus thromboses, intracranial hypertension
 - Pyramidal brainstem lesions
 - Seizures
 - Psychiatric disorders
- Genitourinary
 - Ulcers
 - Epididymitis
 - Glomerulonephritis
 - IgA nephropathy
 - Amyloidosis
 - Renal vein thrombosis
- Gastrointestinal
 - Diarrhea
 - Hemorrhages
 - Ulcers in esophagus, stomach, intestine; may perforate
- Pulmonary (18%)
 - Hemoptysis, dyspnea, chest pain, fever, cough
 - Vascular lesions, pulmonary emboli
 - Aneurysmal bronchial fistula

- Musculoskeletal
 - Arthritis – knee, sacroiliitis, ankylosing spondylitis, non-migrating
-

Imaging

- OCT: CME, CNV, macular atrophy (after vascular insult)
 - FA: CME, retinal vasculitis (may see arteritis, phlebitis, and/or capillaritis), papillitis, vascular occlusion/delay, neovascularization, chorioretinitis
 - Diffuse dye leakage may be seen after inflammation subsides
 - ICG: hypofluorescent choroidal lesions
 - ERG: decreases in overall standard and pattern ERG
-

Laboratory and Radiographic Testing

- No definitive serologic or laboratory testing
 - May be elevated acute phase reactant proteins: ESR, CRP, complement
 - HLA-B51 association (not diagnostic)
 - Elevated soluble CD25 may precede recurrence
-

Differential Diagnosis

- HLA-B27 associated uveitis
 - Reactive arthritis
 - Sarcoidosis
 - Systemic lupus erythematosus
 - ANCA vasculitides
 - Viral retinitis
-

Treatment

- Acute AU: frequent topical corticosteroid +/- cycloplegia
 - Q1h steroid and atropine 1% BID with hyoppyon
- Severe AU or posterior involvement
 - Requires aggressive and urgent therapy
 - Systemic corticosteroids, oral or intravenous (or both)
 - Initiation of immunomodulatory therapy
 - May coordinate with other specialists
- Immunomodulatory therapy
 - Antimetabolites
 - Azathioprine or mycophenolate

- Calcineurin inhibitors
 - Cyclosporine may supplement antimetabolite therapy
- Biologics (especially with RV)
 - TNF α inhibitors – adalimumab, infliximab
 - CD20 inhibition – rituximab
 - Anti-IL1 β – anakinra, canakinumab (used in some cases)
- Alkylating agents
 - Chlorambucil or cyclophosphamide
- Other therapeutic measures
 - Colchicine
 - Plasmapheresis
 - Interferon α -2a
 - Dapsone
 - Pendoxyphilline
 - Penicillin
 - Thalidomide

Referral/Co-management

- Rheumatology
- Cardiology
- Neurology
- Dermatology
- ENT
- Gastroenterology
- Urology
- Pulmonology